In May 2026, Lilly reported that in a late-stage trial of adults with obesity or overweight and at least one weight-related comorbidity, the highest 12 mg dose of retatrutide produced 28.3% average weight loss over 80 weeks, and more than 45% of participants lost 30% or more of their body weight
Semaglutide increases GLP-1 levels, stabilizing blood sugar, slowing stomach emptying, and curbing appetite, leading to weight loss
If obesity indications receive broader federal coverage, expect step-changes in utilization, rebate dynamics, and formulary strategy across markets tied to Medicare benchmarks
Furthermore I wanted to demonstrate how R&D trends in obesity are being reflected in GLP-1 deal making activity
Diabetologia, 54, 27452754